CoChat

Combination Drug Therapy for the Management of Alzheimer’s Disease

Open access

The DOI matches its Crossref record; 135 of the 135 references it cites were found in a registry or an index.

Abstract

Alzheimer’s disease (AD) is the leading cause of dementia worldwide. Even though the number of AD patients is rapidly growing, there is no effective treatment for this neurodegenerative disorder. At present, implementation of effective treatment approaches for AD is vital to meet clinical needs. In AD research, priorities concern the development of disease-modifying therapeutic agents to be used in the early phases of AD and the optimization of the symptomatic treatments predominantly dedicated to the more advanced AD stages. Until now, available therapeutic agents for AD treatment only provide symptomatic treatment. Since AD pathogenesis is multifactorial, use of a multimodal therapeutic intervention addressing several molecular targets of AD-related pathological processes seems to be the most practical approach to modify the course of AD progression. It has been demonstrated through numerous studies, that the clinical efficacy of combination therapy (CT) is higher than that of monotherapy. In case of AD, CT is more effective, mostly when started early, at slowing the rate of cognitive impairment. In this review, we have covered the major studies regarding CT to combat AD pathogenesis. Moreover, we have also highlighted the safety, tolerability, and efficacy of CT in the treatment of AD.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms21093272

Cites

135 of 135 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Chemical structure of one heterodimer of galantamine and memantine.
Figure 1 Chemical structure of one heterodimer of galantamine and memantine.CC BY · PubMed Central
Figure 2 The linking of memantine and nitroglycerin leads to a new drug nitromemantine.
Figure 2 The linking of memantine and nitroglycerin leads to a new drug nitromemantine.CC BY · PubMed Central
Figure 3 Chemical structure of one heterodimer of donepezil and clioquinol.
Figure 3 Chemical structure of one heterodimer of donepezil and clioquinol.CC BY · PubMed Central
Figure 4 The linking of rivastigmine and rasagiline leads to a new drug ladostigil.
Figure 4 The linking of rivastigmine and rasagiline leads to a new drug ladostigil.CC BY · PubMed Central
Figure 5 The linking of VK-28 and propargylamine leads to a new drug M-30.
Figure 5 The linking of VK-28 and propargylamine leads to a new drug M-30.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 135 references

Cited by

See all 218

Metadata

Authors
Kabir, M. T., Uddin, M. S., Mamun, A. A., Jeandet, P., Aleya, L., Mansouri, R. A., Ashraf, G. M., Mathew, B., Bin-Jumah, M. N., & Abdel-Daim, M. M.
Affiliations
  • BRAC University (BD)
  • Southeast University (BD)
  • Centre National de la Recherche Scientifique (FR)
  • King Abdulaziz University (SA)
  • Division of Drug Design and Medicinal Chemistry Research Lab, Department of Pharmaceutical Chemistry, Ahalia School of Pharmacy, Palakkad 678557, India
  • Princess Nourah bint Abdulrahman University (SA)
  • Department of Zoology, College of Science, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia
Corresponding author
Uddin, Md. Sahab
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2020-05-05
Volume
21
Issue
9
Pages
3272
ISSN
1422-0067 (ISSN-L)
OpenAlex
W3022707404
Cited by
217
References
135
Citations by year
2026: 26 · 2025: 43 · 2024: 34 · 2023: 30 · 2022: 40 · 2021: 27 · 2020: 17
FWCI
3.66
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • HAL (submittedVersion, cc-by)
  • HAL (submittedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Griffith Research Online (submittedVersion, cc-by)
Funders
  • Princess Nourah Bint Abdulrahman University
  • Deanship of Scientific Research, Princess Nourah Bint Abdulrahman University
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords
Alzheimer's disease, combination therapy, multimodal therapy, disease-modifying therapy, symptomatic treatment, early intervention, cognitive impairment, drug safety and tolerability, drug efficacy
MeSH terms
Alzheimer Disease, Animals, Cholinesterase Inhibitors, Clinical Trials as Topic, Disease Susceptibility, Drug Therapy, Combination, Galantamine, Humans, Memantine, Dopamine Agents, Biomarkers, Disease Management

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Combination Drug Therapy for the Management of Alzheimer’s Disease. https://app.cochat.ai/papers/10.3390/ijms21093272
The paper
Kabir, M. T., Uddin, M. S., Mamun, A. A., Jeandet, P., Aleya, L., Mansouri, R. A., Ashraf, G. M., Mathew, B., Bin-Jumah, M. N., & Abdel-Daim, M. M. (2020). Combination Drug Therapy for the Management of Alzheimer’s Disease. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms21093272

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.